step 1 trial semaglutide 2.4 mg weight loss nejm 2021 In the REDEFINE phase 3a trial, at a dose of with cagrilintide at a dose of 2.4 mg led to significant body-weight reduction in adults without diabetes and Weight regain and cardiometabolic effects

For those looking to optimize their nutrient intake, we offer quick-access supplements like GLP-1 Daily Support, which is designed to help fill nutritional gaps that can occur when your appetite decreases

Table 1 summarizes the RCTs that measured the weight-reducing effects and the other secondary outcomes of GLP-1RA in PCOS patients

Retatrutide, a triple agonist targeting gastric inhibitory polypeptide (GIP), GLP-1, and glucagon receptors, has achieved highly promising outcomes in its phase 2 trial [22], with weight loss up to 24%

Also, fats help with the absorption of vitamins A, D, E, and K (National Institute of General Medical Sciences 2024)